Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infections Post Transplant

Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation

Bone Marrow Transplantation volume 32, pages 703–707 (2003)Cite this article

Summary:

In contrast to allogeneic bone marrow transplantation (allo-BMT), there is a paucity of data on cytomegalovirus (CMV) infection and pre-emptive therapy (PT) strategies following allogeneic peripheral blood stem cell (allo-PBSC) transplantation. We report here on the patterns of CMV infection in a cohort of 225 patients following sibling donor allo-PBSC transplantation. In an attempt to reduce neutropenia, we used intravenous low-dose short-course (LDSC) ganciclovir (GCV) 5 mg/kg once daily for 21 days as preemptive therapy. A total of 165 recipient–donor pairs were CMV seropositive. An initial episode of viremia (detected by shell vial/tube culture) occurred in 75/165 (45%) at a median of day +35 (17–445) post allo-PBSC. In all, 58 patients received PT with LDSC GCV. Among 58, 55 (94%) completed the 21-day course of PT. A second episode of viremia occurred in 19/58 (33%) at day+80 (50–174) and a third episode in 5/58 (9%) at day+134 (103–218). Among patients receiving LDSC GCV, 5/58(9%) developed disease (four pneumonia, one colitis) at day+211 (63–487). No patient on LDSC GCV exhibited a decline in their ANC below 500/μl and none required growth factors. LDSC GCV is extremely well tolerated and cost-effective as PT for CMV viremia following allo-PBSC transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bowden RA, Slichter SJ, Sayers MH et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246–250.

    CAS  PubMed  Google Scholar 

  2. Miller WJ, McCullough J, Balfour HH et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7: 227–234.

    CAS  PubMed  Google Scholar 

  3. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo- controlled, double-blind trial. Ann Intern Med 1993; 118: 179–184.

    Article  CAS  PubMed  Google Scholar 

  4. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173–178.

    Article  CAS  PubMed  Google Scholar 

  5. Salzberger B, Bowden RA, Hackman RC et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997; 90: 2502–2508.

    CAS  PubMed  Google Scholar 

  6. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601–1607.

    Article  CAS  PubMed  Google Scholar 

  7. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005–1011.

    Article  CAS  PubMed  Google Scholar 

  8. Singhal S, Mehta J, Powles R . Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet. Blood 1994; 84: 2055.

    CAS  PubMed  Google Scholar 

  9. Peggs KS, Preiser W, Kottaridis PD et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000; 111: 782–790.

    CAS  PubMed  Google Scholar 

  10. Reusser P, Einsele H, Lee J et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159–1164.

    Article  CAS  PubMed  Google Scholar 

  11. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820.

    CAS  PubMed  Google Scholar 

  12. Machado CM, Menezes RX, Macedo MC et al. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant 2001; 28: 1053–1059.

    Article  CAS  PubMed  Google Scholar 

  13. Mori T, Okamoto S, Matsuoka S et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 765–769.

    Article  CAS  PubMed  Google Scholar 

  14. Kanda Y, Mineishi S, Saito T et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437–444.

    Article  CAS  PubMed  Google Scholar 

  15. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867–874.

    Article  CAS  PubMed  Google Scholar 

  16. Moretti S, Zikos P, VanLint MT et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 1998; 22: 175–180.

    Article  CAS  PubMed  Google Scholar 

  17. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071.

    CAS  PubMed  Google Scholar 

  18. Sakuma H, Hosoya M, Kanno H et al. Risk of cytomegalovirus infection after peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 49–53.

    Article  CAS  PubMed  Google Scholar 

  19. Trenschel R, Ross S, Husing J et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2000; 25: 665–672.

    Article  CAS  PubMed  Google Scholar 

  20. Manteiga R, Martino R, Sureda A et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Bone Marrow Transplant 1998; 22: 899–904.

    Article  CAS  PubMed  Google Scholar 

  21. Link H, Arseniev L, Ljungman P et al. Cytomegalovirus infections after allogeneic peripheral blood progenitor cell transplantation (PBSCT) – a survey of the infectious disease working party of EBMT. Blood 1997; 90(Suppl. 1): 544a (Abstr. 2424).

    Google Scholar 

  22. Gleaves CA, Smith TF, Shuster EA et al. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984; 19: 917–919.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Swenson PD, Kaplan MH . Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early nuclear antigen. J Clin Microbiol 1985; 21: 669–673.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  25. Vij R, DiPersio J, Venkatraman P et al. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood 2003; 101: 2067–2069.

    Article  CAS  PubMed  Google Scholar 

  26. Meyers JD, Flournoy N, Thomas ED et al. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478–488.

    Article  CAS  PubMed  Google Scholar 

  27. Storch GA, Buller RS, Bailey TC et al. Comparison of PCR and pp65 antigenemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leukocytes from solid-organ transplant recipients. J Clin Microbiol 1994; 32: 997–1003.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Brown RA, Adkins D, Khoury H et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999; 17: 806–812.

    Article  CAS  PubMed  Google Scholar 

  29. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659–1665.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO, USA

    R Vij, H Khoury, R Brown, L T Goodnough, S M Devine, W Blum, D Adkins & J F DiPersio

Authors
  1. R Vij
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Khoury
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L T Goodnough
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S M Devine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Adkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J F DiPersio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Vij.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vij, R., Khoury, H., Brown, R. et al. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation. Bone Marrow Transplant 32, 703–707 (2003). https://doi.org/10.1038/sj.bmt.1704216

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704216

Keywords

This article is cited by

Search

Advanced search

Quick links